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Abstract
Rationale: Speech language pathology is an effective management intervention for chronic cough that persists
despite medical treatment. The mechanism behind the improvement has not been determined but may include
active cough suppression, reduced cough sensitivity or increased cough threshold from reduced laryngeal irritation.
Objective measures such as cough reflex sensitivity and cough frequency could be used to determine whether the
treatment response was due to reduced underlying cough sensitivity or to more deliberate control exerted by
individual patients. The number of treatments required to effect a response was also assessed.
Objective: The aim of this study was to investigate subjective and objective measures of cough before, during and
after speech language pathology treatment for refractory chronic cough and the mechanism underlying the
improvement.
Methods: Adults with chronic cough (n = 17) were assessed before, during and after speech language pathology
intervention for refractory chronic cough. The primary outcome measures were capsaicin cough reflex sensitivity,
automated cough frequency detection and cough-related quality of life.
Results: Following treatment there was a significant improvement in cough related quality of life (Median (IQR) at
baseline: 13.5 (6.3) vs. post treatment: 16.9 (4.9), p = 0.002), objective cough frequency (Mean ± SD at baseline:
72.5 ± 55.8 vs. post treatment: 25 ± 27.9 coughs/hr, p = 0.009), and cough reflex sensitivity (Mean ± SD log C5 at
baseline: 0.88 ± 0.48 vs. post treatment: 1.65 ± 0.88, p < 0.0001).
Conclusions: This is the first study to show that speech language pathology management is an effective
intervention for refractory chronic cough and that the mechanism behind the improvement is due to reduced
laryngeal irritation which results in decreased cough sensitivity, decreased urge to cough and an increased cough
threshold. Speech language pathology may be a useful and sustained treatment for refractory chronic cough.
Trial Registration: Australian New Zealand Clinical Trials Register, ACTRN12608000284369.
Introduction
Chronic cough that persists despite medical treatment
(termed refractory cough) is a difficult problem fre-
quently associated with increased cough reflex sensitivity
[1-3]. Management using speech language pathology is
effective for both refractory cough and its associated
voice disorder [4,5] but the mechanism behind the
symptom improvement has yet to be determined. Cough
reflex hypersensitivity plays an important role in chronic
cough [6,7], and it was hypothesised that speech lan-
guage pathology would either increase the threshold for
cough or reduce cough sensitivity [4]. These effects
could be achieved by either a behavioural approach to
cough suppression or improved vocal hygiene leading to
reduced laryngeal irritation.
This study sought to investigate capsaicin cough reflex
sensitivity and automated cough frequency monitoring in
patients with refractory chronic cough undergoing
speech language pathology intervention. Cough reflex
sensitivity testing and cough frequency monitoring are
two objective measures allowing standardized assessment
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as well as providing an understanding of possible
mechanisms of effect. Capsaicin is an extract of hot pep-
pers and is commonly used as a tussive agent in clinical
research because it induces cough in a safe, dose-depen-
dent and reproducible manner [8-10]. Our aim was to
objectively measure changes in cough reflex sensitivity
and cough frequency prior to, during and after a speech
language pathology treatment programme for refractory
cough.
It was hypothesised that speech language pathology
intervention for chronic cough would result in
decreased cough reflex sensitivity, reduced cough fre-
quency, improvement in clinical outcome and improve-
ment in cough and laryngeal subjective measures. We
also sought to determine how many treatment sessions
a patient required to show an improvement and if these
benefits were maintained post intervention.
Methods
A previous pilot study compared 2 behavioral
approaches (isolated cough suppression techniques and
supportive counselling) for refractory chronic cough
(CC) to a CC control group and showed that there was
no change in cough reflex sensitivity (CRS) measured as
C5 after 1 hour of intervention. These were used to
establish the current study in the following ways;
1) C5 does not respond to isolated behavioural
approaches,
2) C5 does not change after 1 × 1 hour session of an
isolated behavioural approach, and, 3) CRS testing mea-
sured as C5 is a highly reproducible test.
Participants
Adult non-smokers (n = 17) with chronic persistent
cough that was refractory to medical assessment and
treatment [11,12] and who were referred for speech lan-
guage pathology management for cough [4] were eligible
for the study. All participants provided written informed
consent for this study, which was approved by the Uni-
versity of Newcastle’s Human Research Ethics Commit-
tee and the Hunter New England Human Research
Ethics Committee. “For detailed description of the
participants, procedures, and analysis, see additional
file 1: Participant details and results.”
Study Design
Participants attended for a maximum of 6 visits (a base-
line visit, up to 4 treatment visits and a post treatment
visit) over a period of 14 to18 weeks. At visit 1, there
was a voice assessment by a qualified speech language
pathologist. This involved a clinical case history, symp-
tom frequency and severity rating [13], auditory percep-
tual voice analysis and instrumental voice analysis
utilizing acoustic and electroglottographic assessment.
The auditory perceptual analysis was conducted utilizing
the Perceptual Voice Profile by Oates and Russell [14]
whereby 15 perceptual parameters of voice pitch, loud-
ness and quality are rated on a severity scale from nor-
mal to severe. A clinical research officer then
administered several questionnaires, [15-20] and con-
ducted cough reflex sensitivity with capsaicin testing
[8,21] and cough frequency by Leicester Cough Monitor
[22] during the visit period. Visits 2-5 consisted of a 30
minute published speech language pathology pro-
gramme for chronic persistent cough [4] followed by
cough reflex testing and cough frequency. A post treat-
ment visit was conducted 2 to 3 weeks after the final
speech language pathology programme session (Visit 6)
for objective cough monitoring.
Speech Pathology treatment programme for chronic
persistent cough
The speech pathology programme for chronic cough has
been described previously [4] and consisted of four
components: (a) education, (b) specific cough suppres-
sion strategies such as the Cough Suppression Swallow,
Cough Control Breathing or paradoxical vocal fold
movement release breathing techniques, (c) vocal
hygiene training, and (d) psychoeducational counselling.
All participants received each of the four components of
the program.
Capsaicin Cough Reflex Sensitivity (CRS) testing [8,21]
Capsaicin CRS was performed as previously reported
with the addition of a participant urge-to-cough score
[23] where the participant was asked to rate their urge
to cough after each dose inhalation of capsaicin accord-
ing to a modified Borg scale where 0 = “No urge to
cough” up to 10 = “Maximum urge to cough”.
Leicester Cough Monitor (LCM) [22]
The LCM is a digital ambulatory cough monitor and
external free-field microphone [22]. This was attached
to the participant at the beginning of each objective
cough measurement visit and removed at the end of the
visit. The cough frequency collection period therefore
encompassed a recording time of about one hour in
which questionnaires and cough reflex testing were per-
formed. This measurement was used to complement the
cough reflex sensitivity test by measuring any change in
the patient’s frequency of coughing after speech pathol-
ogy intervention. Data stored on the recorder was
downloaded onto a computer where it was analysed by
an automated cough detection algorithm (the Leicester
Cough Algorithm, [24,25]). Cough was defined as a
characteristic explosive sound (throat clears were classi-
fied by operator input as a “non-cough” to be consistent
with CRS cough counting) and reported as coughs/hour.
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Analysis
All analyses were performed using statistical and data
analysis software STATA (Statacorp, Texas, USA). Com-
parisons of log cough sensitivity (measured as C5 and
cough threshold) between baseline and each visit was
undertaken using a generalised linear mixed model
(GLMM) with a random intercept term which takes into
account the repeated observations on individuals. Stan-
dard errors were estimated using bootstrapping [26] and
results were expressed as Mean ± SD. Parametric boot-
strap is a practical tool for addressing problems asso-
ciated with inference from GLMMs by producing
sensible estimates for standard errors. Similar models
were used to examine the change in cough frequency
although data was assumed to have a Poisson distribu-
tion. P values < 0.05 were considered significant.
Figures were produced using GraphPad Prism 4
(GraphPad Software, Inc, California, USA).
Results
Seventeen participants (8 male and 9 female) with a
chronic persistent cough participated in the study. The
participants had a median (IQR) cough duration of 60
(147) months and age of 61 (20) years with normal
spirometry [Table 1]. Co-morbidities included gastroeso-
phageal reflux disease (n = 10), asthma (n = 2), eosino-
philic bronchitis (n = 1) and rhinitis (n = 8). Treatment
trials were implemented for these conditions including
proton pump inhibitors for gastroesophageal reflux
disease, inhaled corticosteroids for asthma and eosino-
philic bronchitis, and nasal corticosteroid and/or antihis-
tamine for rhinitis. When cough proved refractory to
these treatments, speech language pathology was imple-
mented. An initial participant cough assessment per-
formed by a speech language pathologist found that 63%
of participants had abnormal auditory perceptual voice
analysis. There was also a high incidence of abnormal
acoustic and electrographic instrumental voice analysis
[Table 1]. The number of treatment sessions for each
participant was determined by their response to the
therapy; specifically this included the effectiveness of the
technique, the participant’s ability to perform and imple-
ment the technique appropriately, their understanding
of the rationale for the treatment, and availability to
attend treatment sessions. Generally, participants
attended 3 (n = 4) or 4 (n = 9) speech treatment ses-
sions while 3 participants responded rapidly and only
required 2 treatment sessions. One participant only
received 1 treatment session due to personal reasons.
Participant compliance was evaluated through informal
interview between the participant and speech pathologist
at the beginning of each session. Participant compliance
with the speech language pathology programme was
determined to be “good” in 53% of the participants;
“partial” in 35% and 12% were classified as non-
adherent.
Participants responded to the treatment with a signifi-
cant improvement in cough-related quality of life (LCQ,
Table 1 Subject Characteristics.
Subject Characteristics Normal
Range
Number, (M/F) 17 (8/9)
Age, years 61 (20)
Age Range, years 34-83
Cough Duration, months 60 (147)
FEV1, %predicted 88.2 (16.7)
FVC, %predicted 88.5 (20.3)
Auditory perceptual voice analysis, % abnormal 63
Maximum phonation time, seconds 12.8 (8.9) >15
Range, seconds 1 - 26
Jitter, percent 1.7 (1.6) < 1
Range, percent 0.4 - 6.5
Harmonic to noise ratio, dB SPL 15.9 (3.8) > 20
Range, dB SPL 10 - 24.7
Speaking fundamental frequency, Hertz Female: 178 (20) 180 - 200 (female)
Range, Hertz 154 - 198 90-130 (male)
Range, Hertz Male: 110 (14)97 - 133
Closed phase, percent 43.5 (6.4) 44.5
Range, percent 32 - 53
Median (IQR) unless otherwise stated.
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p = 0.002), laryngeal dysfunction symptom questionnaire
score (LDQ, p = 0.003), cough score, p= 0.04 and total
symptoms score, p = 0.002 [Table 2, Figure 1]. There
was a significant improvement in cough reflex sensitivity
measured as C5 with speech language pathology treat-
ment for chronic persistent cough. Cough reflex sensi-
tivity was heightened at baseline, Mean ± SD log C5
0.88 ± 0.48 and significantly improved with treatment to
log C5 1.65 ± 0.88, p < 0.0001 [Individual log C5 data
(baseline v post treatment) represented in Figure 2a].
Improvements in cough reflex sensitivity were apparent
after each visit: treatment visit 1, Mean ± SD log C5
(T1) 1.18 ± 0.62, p = 0.023, treatment visit 2 (T2) log
C5 (T2) 1.46 ± 0.78, p < 0.0001, treatment visit 3 (T3)
log C5 1.45 ± 0.68 p < 0.0001, and treatment visit 4
(T4) log C5 1.53 ± 0.93, p < 0.0001 [Table 3]. These
results indicate that the improvement in cough reflex
sensitivity occurred after the first treatment visit,
increased at subsequent treatment visits (significant
treatment response attained after 2 treatments and max-
imum treatment response after 4 treatments) and that
the effect was sustained at the post treatment visit.
There was also a significant decrease in cough fre-
quency with the speech language pathology treatment
for chronic persistent cough. The cough count at base-
line was reduced after treatment: Mean ± SD cough fre-
quency, 72.5 ± 55.8 vs. 25 ± 27.9 coughs/hr, p = 0.009
[Individual cough frequency data (baseline v post treat-
ment) represented in Figure 2b] and the cough count
tended to reduce each treatment visit and reached sig-
nificance after treatment visit 3: cough frequency Mean
± SD treatment visit 1 (T1) 42.5 ± 60.5 coughs/hr,




Cough Symptom Score (Mean ±
SD)
9.4 ± 4.2 6.2 ± 3.8 0.04







Snot-20 Score 1.3 (1.5) 0.6 (1.3) 0.11
LDQ Score 5 (4) 2 (2) 0.003
HADS Anxiety Score 9.5 (2.0) 11.0 (4.5) 0.33
HADS Depression Score 10 (2) 10 (6) 0.34
Median (IQR) unless otherwise stated.
LCQ = Leicester Cough Questionnaire
GORD = Gastroesophageal reflux disease
Snot-20 = 20-item Sino-Nasal Outcome Test
LDQ = Laryngeal Dysfunction Questionnaire
HADS = Hospital Anxiety and Depression Scale
Figure 1 Cough subjective measures of a) Cough Score b)
Cough Quality of Life and c) Laryngeal Dysfunction (Baseline
vs Post Treatment). Effect of speech-language pathology
treatment on refractory chronic cough outcomes of a) Cough
symptoms scores (Mean ± SD). b) Leicester cough questionnaire
Median (IQR) and c) Laryngeal dysfunction questionnaire Median
(IQR).
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p = 0.23, treatment visit 2 (T2) 63.0 ± 78.8 coughs/hr,
p = 0.34, treatment visit 3 (T3) 48.7 ± 36.8 coughs/hr,
p = 0.005 and treatment visit 4 (T4) 29.4 ± 18.4 coughs/
hr, p < 0.0001 [Table 3]. The effect of the treatment
programme on cough frequency was not as immediate
as the effect on C5 with a significant result occurring
after treatment visit 3 rather than at visit 1. The effect
of treatment on cough frequency continued for treat-
ment visit 4 (maximum treatment response) and was
sustained at the post treatment visit.
Cough threshold at baseline was Mean ± SD log CT
0.47 ± 0.38 and was significantly altered during treat-
ment: treatment visit 1, cough threshold (T1) log CT
0.72 ± 0.60, p = 0.024, treatment visit 2 (T2) log CT 0.80
± 0.60, p = 0.025, treatment visit 3 (T3) log CT 0.69 ±
0.23, p = 0.002, until maximum effect had been achieved
with no significant change at treatment visit 4 (T4) log
CT 0.66 ± 0.65, p = 0.122. After completion of therapy,
cough threshold improved significantly: log CT 1.14 ±
0.76, p = 0.001 [Individual cough threshold data (baseline
v post treatment) represented in Figure 3a].
There was a significant decrease in urge-to-cough with
the speech language pathology treatment for chronic
persistent cough. The urge-to-cough at baseline was
reduced after treatment: Median (IQR), 5 (1) vs. 1 (4),
p = 0.01 [Individual urge to cough data (baseline v post
treatment) represented in Figure 3b] and the urge-to-
cough tended to reduce after each treatment visit and
reached significance after treatment visit 3: urge to
cough Median (IQR) treatment visit 1 (T1) 3.5 (4), p =
0.38, treatment visit 2 (T2) 3 (5), p = 0.61, treatment
visit 3 (T3) 1.5 (3), p = 0.005 and treatment visit 4 (T4)
0.5 (1), p = 0.24.
Discussion
This is the first study to objectively assess response to a
speech language pathology programme for refractory
chronic cough using measures of cough sensitivity and
cough frequency. We have shown that patients with
refractory chronic cough have significantly decreased
cough sensitivity and cough frequency together with an
Figure 2 Objective cough measures of a) Cough Reflex
Sensitivity (C5) and b) Cough Frequency (Baseline vs Post
Treatment). Effect of speech-language pathology treatment on
refractory chronic cough outcomes of a) Log Cough Reflex
Sensitivity at baseline (Base), and post treatment (Post Rx) for
individual data. C5 = capsaicin dose to elicit 5 or more coughs 30
sec after dose administered. b) Cough Frequency at baseline (Base),
and post treatment (Post Rx).
Table 3 Capsaicin Cough Reflex Sensitivity Test, Urge-to-Cough and Leicester Cough Monitor Testing.
Measurement Baseline T1 T2 T3 T4 Post Treatment P*
Log CRS, C5
μMol/L
0.88 ± 0.48 1.18 ± 0.62 1.46 ± 0.78 1.45 ± 0.68 1.53 ± 0.93 1.65 ± 0.88 < 0.0001
Cough Frequency
(coughs/hr)
72.5 ± 55.8 42.5 ± 60.5 63.0 ± 78.9 48.7 ± 36.8 29.4 ± 18.4 25.0 ± 27.9 0.009
Log Cough Threshold
μMol/L
0.47 ± 0.38 0.72 ± 0.60 0.80 ± 0.60 0.69 ± 0.23 0.66 ± 0.65 1.14 ± 0.76 0.001
Urge to Cough Score,
Median (IQR)
5 (1) 3.5 (4.0) 3 (5) 1.5 (3.0) 0.5 (1.0) 1 (4) 0.01
Mean ± SD unless otherwise indicated.
* Baseline vs Post Treatment T = Treatment Post = Post Treatment
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improvement in clinical outcome and cough and laryn-
geal symptoms following the speech language pathology
intervention. Participants had an early symptom
response to the speech language pathology program that
was further improved upon throughout subsequent
treatment sessions. Generally, a patient needed 3 to 4
treatment sessions and the response was maintained
after the intervention ceased.
The speech language pathology program for refractory
CC includes several components, and from a previously
conducted pilot study (presented in the additional data
file 1: Participant details and results) it was found that
isolated components such as specific cough suppression
techniques or counselling were not enough for a patient
to achieve a clinical response. In a previous study [27],
we showed the benefit of the speech language pathology
program combined with a cough diagnostic and treat-
ment algorithm [12] on cough reflex sensitivity in
chronic persistent cough patients with paradoxical vocal
fold movement (PVFM). This study expands on those
results by treating patients with cough that is refractory
to usual medical care with or without the presence of
PVFM and investigating the mechanism of action. Our
aim was to objectively measure changes in cough reflex
sensitivity and cough frequency prior to speech language
pathology program, during the speech pathology lan-
guage program and at a post-treatment visit. We found
that both cough frequency and cough sensitivity
improved progressively with the speech language pathol-
ogy program. Statistically significant improvements in
cough reflex sensitivity were apparent after 1 treatment
session, and this resulted in significant reduction in
cough frequency after 3 sessions.
Within the large population of patients with CC, there
is a small subgroup that does not respond to usual med-
ical treatment [3,28]. In the past this group has been
referred to as chronic idiopathic cough [1]. This group
has been shown to have increased sensitivity to capsai-
cin challenge indicating a heightened cough reflex. The
typical refractory cough patient will have coughing
bouts triggered by normal daily activities such as expo-
sure to aerosols, perfumes, cold air or when talking or
laughing. Patients also describe a ‘tickle, irritation, lump
or blockage’ in the throat preceding the urge to cough.
While the mechanism/s of chronic idiopathic cough are
currently unknown it has been proposed that chronic
idiopathic cough maybe similar to other sensory hyper-
algesias, where there is a long-standing reduction in sen-
sory nerve threshold to stimulation [29,30]. We
previously showed that up to 60% of refractory or idio-
pathic cough can be associated with paradoxical vocal
fold movement - a sensory laryngeal hypersensitivity
with heightened cough reflex sensitivity and extrathor-
acic airway hyperresponsiveness [7]. Both extrathoracic
airway hyperresponsiveness and cough reflex sensitivity
respond to diagnostic medical treatment with the addi-
tion of speech language pathology in chronic cough, and
in the current study we now extend that data to show
that refractory cough with or without PVFM responds
to speech language pathology program for cough that
persists after usual treatments have been exhausted.
This study investigated the mechanism of the improve-
ment in sensory hyperresponsiveness in chronic idio-
pathic cough following a speech language pathology
programme. The mechanism of the effect is due to a
reduction in cough reflex sensitivity. The speech lan-
guage pathology program has several components that
Figure 3 Objective measure-Cough Threshold (a) and
Participants urge-to-cough at C5 (b) (Baseline vs Post
Treatment). Effect of speech-language pathology treatment on
refractory chronic cough outcomes of a) Log Cough Threshold at
baseline (Base), and post treatment (Post Rx). b) Urge to Cough
score at baseline (Base), and post treatment (Post Rx).
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include cough suppression behaviour and vocal hygiene
training. Voluntary cough suppression does not appear
to be the primary mechanism of effect since we saw the
effect of the speech language pathology program on
cough threshold during the treatment programme. This
is also supported by a pilot study where we examined
the individual speech language pathology program com-
ponents and found no effect of the cough suppression
component on cough reflex sensitivity.
The study does suggest that the effective speech lan-
guage pathology programme components reduce
cough reflex sensitivity. This effect could occur by
improvement in vocal hygiene leading to reduce sen-
sory nerve stimulation, and is supported by the
improvements in C5 and urge to cough during the
programme. It is also possible that the reduction in
cough frequency subsequently reduces cough-related
airway trauma, and this explains the delayed improve-
ment in cough threshold.
In this study we used an open design with objective
measures to assess outcome. Although a nonrandomized
design is a limitation, our primary purpose was to treat
refractory cough patients and determine their response
to a therapy outside normal chronic cough treatment.
We achieved this aim by using objective measures and
presenting novel data showing that cough frequency and
cough reflex hypersensitivity significantly improve after
speech language pathology treatment. It is possible that
a placebo effect such as cough suppression [31-33] may
have influenced some of the measures used in this
study. We believe however that this is unlikely as the
majority of the subjects studied had a cough for more
than 5 years duration and underwent numerous cough
treatments prior to speech language pathology interven-
tion. Also, if there was a placebo effect at work then an
improvement in C5 and cough threshold may be seen
but there would be no change in the subjects urge to
cough [23,34] as seen here.
We did not find a heightened cough reflex sensitivity
in CC females compared to CC males (power 90%) and
this was consistent with our previous research [7,27]
(for further results on this refer to additional file 1: Par-
ticipant details and results). A gender difference in
cough reflex sensitivity has been reported in some
healthy subjects without cough [35,36] but not all [37]
studies. We studied subjects representative of those with
refractory chronic persistent cough. They were primarily
middle-aged with a significant cough duration, had been
treated for the usual causes of cough [12] and had not
responded to those treatments. We assessed cough
reflex sensitivity to capsaicin and cough frequency using
validated techniques [8,21,22] and present novel data on
how this group respond to speech language pathology
treatment for chronic cough.
Conclusion
In conclusion, this is the first study to show that speech
language pathology management is an effective interven-
tion for refractory chronic cough and that the mechan-
ism behind the improvement is due to reduced laryngeal
irritation which results in decreased cough sensitivity,
decreased urge to cough and an increased cough thresh-
old. This is accompanied with an improvement in cough
symptoms, associated laryngeal symptoms, and cough
quality of life. Speech language pathology may be a use-
ful therapy for refractory chronic cough.
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